IMBRUVICA (ibrutinib) is used for the treatment of patients with mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia.

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with Mantle cell lymphoma (MCL) who have received at least one prior treatment, Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL), Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion, Waldenström's macroglobulinemia (WM) Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment, Chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy.

IMBRUVICA (ibrutinib) suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of IMBRUVICA (ibrutinib) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 / 9891296838 or Email Us to know more details about the medicine and its cost price in India.

The order for IMBRUVICA (ibrutinib) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Ibrutinib (Imbruvica) is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK), that is important in B cells. It is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. Ibrutinib is used to treat chronic lymphocytic leukemia (CLL), Waldenström's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, marginal zone lymphoma, and chronic graft vs host disease. It is a first line treatment in those with CLL who require treatment and are newly diagnosed. It may also be used in CLL that relapses.

IMBRUVICA® (ibrutinib) capsules, for oral use. Initial U.S. Approval: 2013

Generic Name: ibrutinib

IMBRUVICA (ibrutinib)

IMBRUVICA (ibrutinib) capsules, for oral use is available.

Get In Touch

Indian Pharma Network (IPN), Delhi. India

IPN, Delhi is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India. IPN, New Delhi helps patient, providing solutions on how to get access of anti cancer medicines which is not available in India.


Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

IMBRUVICA (ibrutinib) suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand IMBRUVICA (ibrutinib) on prescription and Import License in Patient's Name only.

For overseas patients, IMBRUVICA (ibrutinib) can be made available in Send your enquiry to find IMBRUVICA (ibrutinib) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for Mektovi (Binimetinib).

Janssen Announces European Commission Approval of Imbruvica®▼(ibrutinib) for Expanded Use in Two Indications For More Details

RESONATE final analysis confirms efficacy of ibrutinib in patients with R/R CLL. For More Details